Phase II Clinical Trial of Etanercept Plus Extracorporeal Photopheresis GVHD Prophylaxis Following Unrelated Donor Reduced Intensity Transplant

被引：0
|
作者：
Kitko, Carrie L. [1 ]
Braun, Thomas [2 ]
Schuler, Charles [3 ]
Choi, Sung Won [1 ]
Yanik, Gregory [1 ]
Pawarode, Attaphol [4 ]
Magenau, John [4 ]
Taylor, Austin [5 ]
Ferrara, James L. M. [5 ]
Couriel, Daniel R. [4 ]
Levine, John [1 ]
机构：
[1] Univ Michigan, Pediat Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Adult Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2014.11.537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
490
引用
收藏
页码：S337 / S337
页数：1
相关论文
共 50 条
  • [31] A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids
    Alousi, Amin M.
    Bassett, Roland
    Chen, Julianne
    Overman, Bethany J.
    Hosing, Chitra M.
    Popat, Uday R.
    Shpall, Elizabeth J.
    Nieto, Yago
    Qazilbash, Muzaffar H.
    Khouri, Issa F.
    Kebriaei, Partow
    Ahmed, Sairah
    Shah, Nina
    Rezvani, Katayoun
    Kondo, Kayo
    Ciurea, Stefan O.
    Hymes, Sharon R.
    Neumann, Joyce L.
    Molldrem, Jeffrey J.
    Plair, Tamera R.
    Champlin, Richard E.
    BLOOD, 2015, 126 (23)
  • [32] A Randomized Phase II Study Comparing Cyclosporine and Sirolimus Combined with MMF or Post-Transplant Cyclophosphamide As Gvhd Prophylaxis after HLA-Matched or-Mismatched Unrelated Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced-Intensity Conditioning
    Oshima, Masumi Ueda
    Vo, Phuong
    Gooley, Ted A.
    Bouvier, Michelle E.
    Carpenter, Paul A.
    Mielcarek, Marco
    Petersdorf, Effie W.
    Sandmaier, Brenda M.
    TRANSPLANTATION AND CELLULAR THERAPY, 2025, 31 (02): : S5 - S5
  • [33] Correction to: A phase II study of post‑transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA‑matched related/unrelated allogeneic hematopoietic stem cell transplantation
    Hirohisa Nakamae
    Takahiko Nakane
    Hiroshi Okamura
    Hideo Koh
    Yasuhiro Nakashima
    Asao Hirose
    Mika Nakamae
    Mitsutaka Nishimoto
    Masatomo Kuno
    Yosuke Makuuchi
    Naonori Harada
    Teruhito Takakuwa
    Masayuki Hino
    International Journal of Hematology, 2022, 115 : 146 - 146
  • [34] Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation
    Jamy, Omer
    Innis-Shelton, Raquel
    Bal, Susan
    Paluri, Ravi
    Salzman, Donna
    Di Stasi, Antonio
    Costa, Luciano
    Meredith, Ruby
    Lamb, Lawrence
    Minagawa, Kentaro
    Mineishi, Shin
    Saad, Ayman
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (10) : E396 - E398
  • [35] A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation
    Jamy, Omer
    Innis-Shelton, Racquel
    Bal, Susan
    Paluri, Ravi K.
    Karim, Samina
    Chewning, Joseph H.
    Salzman, Donna
    Costa, Luciano J.
    Di Stasi, Antonio
    Lamb, Lawrence S., Jr.
    Mineishi, Shin
    Saad, Ayman
    BLOOD, 2019, 134
  • [36] Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial
    Abraham, Allistair
    Cluster, Andrew
    Jacobsohn, David
    Delgado, David
    Hulbert, Monica L.
    Kukadiya, Divyesh
    Murray, Lisa
    Shenoy, Shalini
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (09) : 1587 - 1592
  • [37] A Phase II Clinical Trial of Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prevention Following Myeloablative Peripheral Blood Stem Cell Matched Unrelated Donor Hematopoietic Stem Cell Transplantation
    Jamy, Omer
    Innis-Shelton, Racquel
    Bal, Susan
    Salzman, Donna
    Costa, Luciano J.
    di Stasi, Antonio
    Lamb, Lawrence
    Mineishi, Shin
    Saad, Ayman
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S190 - S191
  • [38] In vivo T-cell depletion with antithymocyte globulin or alemtuzumab for unrelated donor stem cell transplantation with reduced intensity conditioning: results of a multicentre randomized phase II clinical trial (the Global study) from the GITMO
    Algarotti, A.
    Mico, C.
    Corradini, P.
    Falda, M.
    Alessandrino, E. P.
    Fanin, R.
    Tagliaferri, E.
    Castagna, L.
    Mordini, N.
    Sica, S.
    Santarone, S.
    Levis, A.
    Iori, A.
    Pollichieni, S.
    Sacchi, N.
    Scarano, M.
    Masciulli, A.
    Marchioli, R.
    Bacigalupo, A.
    Bosi, A.
    Rambaldi, A.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S60 - S61
  • [39] Prophylaxis with mycophenolate mofetil and cyclosporine can decrease the incidence of severe acute GvHD following reduced-intensity conditioning allogeneic stem cell transplantation from matched unrelated donors
    Brissot, E.
    Chevallier, P.
    Guillaume, T.
    Delaunay, J.
    Ayari, S.
    Dubruille, V.
    Le Gouill, S.
    Mahe, B.
    Gastinne, T.
    Blin, N.
    Saulquin, B.
    Moreau, P.
    Harousseau, J. L.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S128 - S129
  • [40] Reduced intensity conditioning regimen for unrelated cord blood transplantation in adults.: A multicentric phase I-II trial.
    Belhocine, R
    Renaud, M
    François, S
    Gluckman, E
    Blaise, D
    Rocha, V
    BLOOD, 2005, 106 (11) : 1018A - 1018A
12345